Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Response and resistance to first and second generation TRK inhibitors in an NTRK1-driven sarcoma

ABSTRACT: Response and resistance to first and second generation TRK inhibitors in an NTRK1-driven sarcoma

PROVIDER: PRJNA548088 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
	SRR9257360.fastq.gz	Fastqsanger.gz
	SRR9257361.fastq.gz	Fastqsanger.gz
	SRR9257362.fastq.gz	Fastqsanger.gz
	SRR9257357.fastq.gz	Fastqsanger.gz
	SRR9257358.fastq.gz	Fastqsanger.gz

Items per page:

1 - 5 of 6

Similar Datasets

Response and resistance to first and second generation TRK inhibitors in an NTRK1-driven sarcoma

Project description:We report here a patient with a TPM3-NTRK1 translocated sarcoma who developed resistance to larotrectenib arising from the p.G595R solvent-front substitution. The patient was treated with LOXO-195 with initial response followed by subsequent resistance. Molecular profiling of the resistant tumor identified a KRAS p.G12V substitution, with associated activation of KRAS signaling and immune infiltration into the tumor. Following cytoreductive surgery to remove the resistant lesion, the patient’s disease has continued to respond to LOXO-195.

2022-05-23 | GSE132439 | GEO

RNA-seq of human first and second trimester placenta

Project description:RNA-seq of human first and second trimester placenta

| PRJEB38810 | ENA

scATAC-seq of first and second-trimester human gonads

Project description:scATAC-seq of first and second-trimester human gonads

| PRJEB52512 | ENA

Multiomic snRNAseq/snATACseq of first and second-trimester human gonads

Project description:Multiomic snRNAseq/snATACseq of first and second-trimester human gonads

| PRJEB52752 | ENA

Spatial transcriptomics (Visium) of first and second-trimester human gonads

Project description:Spatial transcriptomics (Visium) of first and second-trimester human gonads

| PRJEB54898 | ENA

multiomic snRNAseq/snATACseq of first and second-trimester human gonads

Project description:multiomic snRNAseq/snATACseq of first and second-trimester human gonads

| PRJEB64599 | ENA

scATAC-seq of first and second-trimester human gonads

Project description:Comprehensive map of first- and second-trimester gonadal development in humans using a combination of single-cell and spatial transcriptomics, chromatin accessibility assays, and imaging.

2024-02-05 | E-MTAB-10570 | biostudies-arrayexpress

scRNA-seq of first and second trimester human gonads - 10x dataset

Project description:scRNA-seq of first and second trimester human gonads - 10x dataset

| PRJEB52626 | ENA

Paternal methamphetamine exposure differentially affects first and second generations in mice

Project description:Paternal methamphetamine exposure differentially affects first and second generations in mice

| PRJNA1044753 | ENA

Illuminating phenotypic drug responses of sarcoma cells to kinase inhibitors by phosphoproteomics

Project description:Kinase inhibitors (KIs) are important cancer drugs but often display polypharmacology that is molecularly not understood. This disconnect is particularly apparent in cancer entities such as sarcomas for which the oncogenic drivers are often not clear. To investigate more systematically how the cellular proteotypes of sarcoma cells shape their response to molecularly targeted drugs, we profiled the proteomes and phosphoproteomes of 17 sarcoma cell lines and screened the same cells against 150 cancer drugs. The resulting 2,550 phenotypic drug profiles revealed distinct drug responses and the cellular activity landscapes derived from deep (phospho)proteomes (9-10,000 proteins and 10-27,000 phosphorylation sites per cell line) enabled several lines of analysis. For instance, connecting the (phospho)proteomic data with drug responses revealed known and novel mechanisms of action (MoAs) of kinase inhibitors and identified markers of drug sensitivity or resistance. All data is publically accessible via an interactive web application that enables exploration of this rich molecular resource for better understanding active signalling pathways in sarcoma cells, identifying treatment response predictors, and revealing novel MoA of clinical KIs.

2023-01-11 | MSV000091043 | MassIVE

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data